J. Kirkwood, “Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma”, J of Skin, vol. 5, no. 1, p. s2, Jan. 2021.